Markets & Investing
Why Alts.Co Invested in the Psychedelics Industry (LIVE EVENT)
Nucleus CEO, Logan Lenz, sits down with Stefan von Imhof, the CEO of Alts.co to discuss Nucleus and the massive opportunity for the psychedelics industry…
Nucleus CEO, Logan Lenz, sits down with Stefan von Imhof, the CEO of Alts.co to discuss Nucleus and the massive opportunity for the psychedelics industry in the coming years.
A few months back, Alts published a deep dive on Nucleus, a venture studio for psychedelics (and Psychedelic Invest’s parent company).
Stefan is the co-founder and CEO of Alts.co. He’s a huge fan of alternative investing and has a strong background in alternative asset analysis and valuations. Prior to co-founding Alts.co, Stefan was Head of Product at Flippa where he created Flippa’s Due Diligence Program, He also spent time at Citrix and lynda.com, which was bought by LinkedIn, and was the first product manager at HG Insights, a market intelligence company that sold to Riverwood Capital Partners in 2020. Originally from Boston and later Santa Barbara, CA, he now lives in Australia with his wife & Boston Terrier, Charlie.
More About Alts.co
Alts.co provides original research and insights you can trust on alternative assets. Over 85,000 subscribers are delivered investment opportunities and insights straight to their inbox.
Investing in Nucleus
For those who don’t know by now, Nucleus currently allows anyone to invest in the company with as little as $200. All you must do is visit the Wefunder page, select your investment amount, and go through Wefunder’s transaction process.
Stay tuned for more Nucleus events and webinars as the campaign continues.
RSVP To Reserve Your Spot
-
Psychedelics7 days ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin6 days ago
Are Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week ago
Numinus reports declining revenue as the company restructures
-
Law & Regulation7 days ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psychedelics7 days ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics7 days ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Psychedelics6 days ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation5 days ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights